Cormorant Asset Management, LP Portfolio Holdings

Cormorant Asset Management, LP

  • $628 Million
  • Q3 2025

Cormorant Asset Management, LP has filed its 13F form on November 14, 2025 for Q3 2025 where it was disclosed a total value porftolio of $628 Million distributed in 36 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Eye Point Pharmaceuticals, Inc. with a value of $115M, Bridge Bio Pharma, Inc. with a value of $72.7M, Edgewise Therapeutics, Inc. with a value of $65M, Arcellx, Inc. with a value of $63.6M, and Insmed Inc with a value of $61.9M.

Examining the 13F form we can see an decrease of $364M in the current position value, from $992M to 628M.

Cormorant Asset Management, LP is based out at Boston, MA

Below you can find more details about Cormorant Asset Management, LP portfolio as well as his latest detailed transactions.

Portfolio value $628 Million
Healthcare: $628 Million

Stock Holdings Table Market Cap. of $50 Millions to $300 Millions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$67M
$11.7 Million 1.86% of portfolio
5,000,000
Q2 2025 New

Summary

  • Portfolio
  • No. of Stocks 36
  • Current Value $628 Million
  • Prior Value $992 Million
  • Filing
  • Period Q3 2025
  • Filing Date November 14, 2025
  • Form Type 13F-HR
  • Activity in Q3 2025
  • New Purchases 3 stocks
  • Additional Purchases 3 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 12 stocks
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email